Immunodominance: a new hypothesis to explain parasite escape and host/parasite equilibrium leading to the chronic phase of Chagas' disease? by Rodrigues, Mauricio Martins et al.
220
Braz J Med Biol Res 42(3) 2009
M.M. Rodrigues et al.
www.bjournal.com.br
Immunodominance: a new hypothesis to
explain parasite escape and host/parasite
equilibrium leading to the chronic phase of
Chagas’ disease?
M.M. Rodrigues, B.C.G. de Alencar, C. Claser and F. Tzelepis
Centro Interdisciplinar de Terapia Gênica, Escola Paulista de Medicina, Universidade Federal de São
Paulo, São Paulo, SP, Brasil
Correspondence to: M.M. Rodrigues, CINTERGEN, EPM, UNIFESP, Rua Mirassol, 207, 04044-010 São
Paulo, SP, Brasil
Intense immune responses are observed during human or experimental infection with the digenetic protozoan parasite
Trypanosoma cruzi. The reasons why such immune responses are unable to completely eliminate the parasites are unknown.
The survival of the parasite leads to a parasite-host equilibrium found during the chronic phase of chagasic infection in most
individuals. Parasite persistence is recognized as the most likely cause of the chagasic chronic pathologies. Therefore, a key
question in Chagas’ disease is to understand how this equilibrium is established and maintained for a long period. Understanding
the basis for this equilibrium may lead to new approaches to interventions that could help millions of individuals at risk for
infection or who are already infected with T. cruzi. Here, we propose that the phenomenon of immunodominance may be
significant in terms of regulating the host-parasite equilibrium observed in Chagas’ disease. T. cruzi infection restricts the
repertoire of specific T cells generating, in some cases, an intense immunodominant phenotype and in others causing a dramatic
interference in the response to distinct epitopes. This immune response is sufficiently strong to maintain the host alive during the
acute phase carrying them to the chronic phase where transmission usually occurs. At the same time, immunodominance
interferes with the development of a higher and broader immune response that could be able to completely eliminate the parasite.
Based on this, we discuss how we can interfere with or take advantage of immunodominance in order to provide an
immunotherapeutic alternative for chagasic individuals.
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Chagas’ disease is an acute or chronic illness caused
by the digenetic protozoan parasite Trypanosoma cruzi.
Currently, there are more than 15 million chronically in-
fected individuals in the Americas. These individuals will
carry the parasite for life in a process in which parasite and
host reach a life-long equilibrium. This type of equilibrium
greatly benefits the parasite because it increases the time
for successful transmission to the blood feeding Triatominae
host. In a group of individuals (~30%), this equilibrium will
be broken and the individuals will develop the symptomatic
forms of the disease characterized by damage of the heart
and/or autonomic denervation of the digestive tract.
Parasite-host equilibrium leads to parasite persistence,
which is considered to be the most likely cause of the
chagasic chronic pathologies (1,2). Therefore, a key ques-
tion in Chagas’ disease is to understand how this equilib-
rium is established, allowing both to survive for a long
period. Understanding the basis for this equilibrium may
lead to new interventions that could potentially help mil-
lions of individuals at risk for infection and chronically
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infected with T. cruzi. We propose that the phenomenon of
immunodominance may be quite significant in terms of
regulating the host-parasite equilibrium observed in Chagas’
disease. In addition, we discuss how we can interfere with
or take advantage of immunodominance in order to pro-
vide an immunotherapeutic alternative for individuals at
risk for infection or already infected with T. cruzi.
Following initial infection with T. cruzi, the vast majority
of individuals survive acute infection due to the presence of
adaptive immune responses mediated by class I and class
II major histocompatibility complex (MHC-I and MHC-II)
restricted T cells. Studies in experimental models have
been instrumental in establishing that the removal of MHC-
I or MHC-II restricted T cells leads to extreme susceptibility
and mouse death following acute infection (3). In spite of
the protective immune responses, sterile immunity is rarely
achieved in chagasic individuals and parasite survival
within the host establishes a life-long chronic infection.
Adaptive host immune responses are dependent on
MHC molecules. Pathogens have a number of potential
amino acid sequences that can bind to MHC-I or -II mol-
ecules and provide targets for specific T cells. On the other
hand, hosts have a vast number of T cell receptors (TCR)
that are clonally distributed on these T cells to recognize a
variety of MHC-peptide complexes. In spite of this large
number of possible combinations, pathogen-specific T
cells seem to preferentially recognize a small number of
epitopes. This preference, known as immunodominance,
may be due to different mechanisms including the forma-
tion of stable MHC-peptide complexes on the surface of
antigen presenting cells, higher amounts or a higher af-
finity of specific T cell precursors and competition of T cells
for antigen presenting cells (4-6).
In the case of self-resolving common acute viral or
bacterial infections, immunodominance focuses the re-
sponse on a few determinants. It has been proposed (6)
that this strategy successfully maximizes the power of
effector immune responses and, at the same time, mini-
mizes the risk of auto-immunity. The phenomenon of
immunodominance most likely evolves from the interac-
tion between vertebrate immune systems and these com-
mon acute viral and bacterial diseases. However, in the
case of chronic infections such as Chagas’ disease, the
impact of immunodominance is completely obscure and
may even be harmful to the host.
It was initially considered to be difficult to conduct
studies on the immunodominance of T cell immune re-
sponses during T. cruzi infection due to a large parasite
genome, which contains more than 12,000 genes. Never-
theless, two recent studies have described immunodomi-
nant epitopes recognized by murine and human CD8 T
cells (7,8). During the acute phase of Chagas’ disease,
immunodominance may have an impact similar to that
observed in the viruses and bacteria causing acute infec-
tions, as it guarantees host survival. However, on the
negative side, immunodominance may not allow for an
immune response that is broad enough to completely
eliminate the parasites. In that case, it would be a key
factor restricting the magnitude of the immune response,
allowing parasite survival and providing the means to
establish the parasite/host equilibrium observed during
the chronic life-long infection (see Figure 1).
The fact that immunodominance restricts specific im-
mune responses to T. cruzi poses the question of who
could benefit from such a restriction. A limitation on the
magnitude and specificity of the immune response could
be important for the host to avoid excessive immunopa-
thology. We have evidence against this hypothesis. Fol-
lowing vaccination with plasmid DNA or recombinant pro-
teins, we generated memory CD8 T cells that displayed a
very fast anamnestic immune response after a challenge
with T. cruzi (7). These cells were specific for immunodom-
inant CD8 epitopes. In fact, it led to a reduced parasite
development and prevented the establishment of chronic
phase tissue pathologies. Also, some of these vaccinated
mice completely cleared the parasite. Such a strong im-
mune response did not cause any discernible immunopa-
thology (9-11). However, the fact that the immune re-
sponse of the vaccinated mice may be even more bias to
the immunodominant epitope precludes conclusions on
the immunopathological role of T cells of other specificity.
Figure 1. New theory to explain the chronic phase of Chagas’
disease.
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Alternatively, immunodominance may hamper the de-
velopment of stronger immune responses and aid the
parasites in causing disease and establishing a chronic
infection. This hypothesis is also supported by our vacci-
nation studies in which we dramatically increase the im-
mune response to these immunodominant epitopes fol-
lowing challenge. Under these circumstances, we ob-
tained reduced parasitism and limited disease develop-
ment. Also, in some cases, we reached sterile protection
against T. cruzi, showing that vaccination could be a useful
approach to boost the host immunodominant response (9-
12). We concluded that aberrantly high immunodominant
responses may, in some cases, clear the parasite from the
host. Whether it occurs in non-immune naive individuals
remains to be determined.
If immunodominance were indeed so critical for T. cruzi
survival, a very powerful mechanism would have to be
used to restrict the activation of T cells specific to the non-
immunodominant epitopes. One of the most powerful mech-
anisms to establish immunodominance is the interference
or competition between T cells restricted by distinct MHC
molecules (cross-competition). This mechanism has been
described in a number of experimental models; however,
whether it really occurs during infections is still a matter of
debate (4-6,13).
While studying the mechanism underlying immuno-
dominance during T. cruzi infection in mice, we found that
a strong cross-competition occurs during the priming of T.
cruzi-specific CD8 T cells. This mechanism is extremely
powerful and severely narrows the immune response and
generates immunodominance. Therefore, T cells specific
for a single epitope can block the development of immunity
to several other epitopes, reducing the magnitude and
breadth of the immune response and eventually favoring
parasite escape (14).
This hypothesis, however, could create a severe bottle-
neck. The parasite requires at least one immunodominant
epitope to be recognized by CD4 and CD8 T cells in each
individual. In view of the variation of MHC and the number
of mammals that T. cruzi infects, this could be a severe
problem. For example, the lack of a CD8 T cell epitope
could lead to a high parasitemia and to the death of the
host in the acute phase before transmission. How can the
presence of at least one epitope for every host MHC be
ensured? The genome sequence of T. cruzi identified
families of proteins that have up to 1340 genes. We pro-
pose that the gene duplication process helps to provide at
least one immunodominant epitope for each mammalian
host. Our proposal is supported by the observation that the
immunodominant CD8 epitopes described so far are mem-
bers of a larger family of genes, the trans-sialidase. Dis-
tinct members of this family are recognized by CD8 T cells
restricted by different mouse haplotypes (7,8,12).
Many pathogens establish chronic infections as is the
case for T. cruzi. Whether similar mechanisms contribute to
the chronic process may be an important question to ad-
dress. Some of these pathogens have a high mutation rate
and, in these cases, the immune response relying mainly on
few immunodominant CD8+ T cell epitopes may favor the
escape of immune response associated with pathogen mu-
tation or any particular antigenic variation process. An ex-
ample supporting this hypothesis was described in a human
viral infection with hepatitis C virus. A strong immunodomi-
nant human CD8 T cell response was developed, causing
an escape mutant to be selected (15). Whether dominant
immune responses select for T. cruzi mutants has never
been pursued in depth and should be evaluated in different
experimental models and chagasic patients. However, a
single recent report was unable to detect the presence of
mutant parasites following vaccination of BALB/c mice with
a T. cruzi trans-sialidase recombinant antigen (16).
Previous studies have suggested the presence of immu-
nosuppression and/or polyclonal activation of the immune
response during experimental T. cruzi infection (17,18).
Using concomitant immunization with recombinant adenovi-
rus and infection with T. cruzi, we were unable to detect any
immunosuppressive activity on the in vivo cytotoxic activity
of T. cruzi-specific or non-specific CD8+ T cells (Mello S,
Rodrigues MM, unpublished results). Also, experiments in
vivo failed to detect any polyclonal activation of CD8+ T cells.
TCR transgenic CD8+ OT-1 cells specific for ovalbumin were
adoptively transferred to naive mice. Upon infection with T.
cruzi, these cells failed to proliferate. This evidence strongly
argues against in vivo polyclonal activation (19). The previ-
ously described polyclonal activation described most likely
reflected activation of a large number of specific T cells as
proposed by Martin et al. (8).
We propose that immunodominance may be the stron-
gest mechanism of escape used by T. cruzi. Based on that
assumption, the means to break the deadlock is through
increasing and/or broadening the immune responses prior
to and/or during infection (9-11). Whether immunotherapy
should focus on dominant, subdominant, or cryptic epi-
topes or on all of them at the same time can be addressed
experimentally in the near future and may provide the
basis for rational interventions.
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